Levora (Page 5 of 8)


See WARNINGS section.


Pregnancy Category X. See CONTRAINDICATIONS and WARNINGS sections.


Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.


See PATIENT LABELING printed below.


An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section):

Arterial thromboembolism
Pulmonary embolism
Myocardial infarction
Cerebral hemorrhage
Cerebral thrombosis
Gallbladder disease
Hepatic adenomas, carcinomas or benign liver tumors

There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:

Mesenteric thrombosis
Retinal thrombosis

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:

Gastrointestinal symptoms (such as abdominal cramps and bloating)
Breakthrough bleeding
Change in menstrual flow
Temporary infertility after discontinuation of treatment
Melasma which may persist
Breast changes: tenderness, enlargement, secretion
Change in weight (increase or decrease)
Change in cervical erosion and secretion
Diminution in lactation when given immediately postpartum
Cholestatic jaundice
Rash (allergic)
Mental depression
Reduced tolerance to carbohydrates
Vaginal candidiasis
Change in corneal curvature (steepening)
Intolerance to contact lenses

The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:

Pre-menstrual syndrome
Changes in appetite
Cystitis-like syndrome
Loss of scalp hair
Erythema multiforme
Erythema nodosum
Hemorrhagic eruption
Impaired renal function
Hemolytic uremic syndrome
Budd-Chiari syndrome
Changes in libido


Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.


The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol.6–11

Effects on menses:

Increased menstrual cycle regularity
Decreased blood loss and decreased incidence of iron deficiency anemia
Decreased incidence of dysmenorrheal

Effects related to inhibition of ovulation:

Decreased incidence of functional ovarian cysts
Decreased incidence of ectopic pregnancies

Effects from long-term use:

Decreased incidence of fibroadenomas and fibrocystic disease of the breast
Decreased incidence of acute pelvic inflammatory disease
Decreased incidence of endometrial cancer
Decreased incidence of ovarian cancer


To achieve maximum contraceptive effectiveness, oral contraceptives must be taken exactly as directed and at intervals not exceeding 24 hours.

For a DAY 1 START, count the first day of menstrual flow as Day 1 and the first tablet (white) is then taken on Day 1. For a SUNDAY START when menstrual flow begins on or before Sunday, the first tablet (white) is taken on that day. With either a DAY 1 START or SUNDAY START, 1 tablet (white) is taken each day at the same time for 21 days. Then the peach tablets are taken for 7 days, whether bleeding has stopped or not. After all 28 tablets have been taken, whether bleeding has stopped or not, the same dosage schedule is repeated beginning on the following day.


To achieve maximum contraceptive effectiveness, the oral contraceptive pill must be taken exactly as directed and at intervals not exceeding 24 hours.
Important: Women should be instructed to use an additional method of protection until after the first 7 days of administration in the initial cycle.
Due to the normally increased risk of thromboembolism occurring postpartum, women should be instructed not to initiate treatment with oral contraceptives earlier than 4 weeks after a full-term delivery. If pregnancy is terminated in the first 12 weeks, the patient should be instructed to start oral contraceptives immediately or within 7 days. If pregnancy is terminated after 12 weeks, the patient should be instructed to start oral contraceptives after 2 weeks.33, 77
If spotting or breakthrough bleeding should occur, the patient should continue the medication according to the schedule. Should spotting or breakthrough bleeding persist, the patient should notify her physician.
If the patient misses 1 pill, she should be instructed to take it as soon as she remembers and then take the next pill at the regular time. The patient should be advised that missing a pill can cause spotting or light bleeding and that she may be a little sick to her stomach on the days she takes the missed pill with her regularly scheduled pill. If the patient has missed more than one pill, see DETAILED PATIENT LABELING: HOW TO TAKE THE PILL, WHAT TO DO IF YOU MISS PILLS.
Use of oral contraceptives in the event of a missed menstrual period:
If the patient has not adhered to the prescribed dosage regimen, the possibility of pregnancy should be considered after the first missed period and oral contraceptives should be withheld until pregnancy has been ruled out.
If the patient has adhered to the prescribed regimen and misses consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.


Levora® 0.15/30-28 (levonorgestrel and ethinyl estradiol tablets USP): NDC 42254-260-28

Each white tablet is unscored, round in shape, with 15/30 debossed on one side and WATSON on the other side, and contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol. Levora® 0.15/30-28 is packaged in cartons of six tablet dispensers. Each tablet dispenser contains 21 white (active) tablets and 7 peach (inert) tablets. Inert tablets are unscored, round in shape with WATSON debossed on one side and P1 on the other side.

Store at controlled room temperature 15°-25°C (59°-77°F).


1. Hatcher, R.A. Trussell, J. Stewart, F., et al.: Contraceptive Technology: Sixteenth Revised Edition, New York, NY, 1994. 2. Mann, J., et al.: Br Med J 2 (5956): 241–245, 1975. 3. Knopp, R.H.: J Reprod Med 31 (9): 913–921, 1986. 4. Mann, J.I., et al.: Br Med J 2: 445–447, 1976. 5. Ory, H.: JAMA 237: 2619–2622, 1977. 6. The Cancer and Steroid Hormone Study of the Centers for Disease Control: JAMA 249 (2): 1596– 1599, 1983. 7. The Cancer and Steroid Hormone Study of the Centers for Disease Control: JAMA 257 (6): 796–800, 1987. 8. Ory, H.W.: JAMA 228 (1): 68–69, 1974. 9. Ory, H.W., et al.: N Engl J Med 294: 419–422, 1976. 10. Ory, H.W.: Fam Plann Perspect 14: 182–184, 1982. 11. Ory, H.W., et al.: Making Choices, New York, The Alan Guttmacher Institute, 1983. 12. Stadel, B.: N Engl J Med 305 (11): 612–618, 1981. 13. Stadel, B.: N Engl J Med 305 (12): 672–677, 1981. 14. Adam, S., et al.: Br J Obstet Gynaecol 88: 838–845, 1981. 15. Mann, J., et al.: Br Med J 2 (5965): 245–248, 1975. 16. Royal College of General Practitioners’ Oral Contraceptive Study: Lancet 1: 541–546, 1981. 17. Slone, D., et al.: N Engl J Med 305 (8): 420–424, 1981. 18. Vessey, M.P.: Br J Fam Plann 6 (supplement): 1–12, 1980. 19. Russell-Briefel, R., et al.: Prev Med 15: 352–362, 1986. 20. Goldbaum, G., et al.: JAMA 258 (10): 1339–1342, 1987. 21. LaRosa, J.C.: J Reprod Med 31 (9): 906–912, 1986. 22. Krauss, R.M., et al.: Am J Obstet Gynecol 145: 446–452, 1983. 23. Wahl, P., et al.: N Engl J Med 308 (15): 862–867, 1983. 24. Wynn, V., et al.: Am J Obstet Gynecol 142 (6): 766–771, 1982. 25. Wynn, V., et al.: J Reprod Med 31 (9): 892–897, 1986. 26. Inman, W.H., et al.: Br Med J 2 (5599): 193–199, 1968. 27. Maguire, M.G., et al.: Am J Epidemiol 110 (2): 188–195, 1979. 28. Petitti, D., et al.: JAMA 242 (11): 1150–1154, 1979. 29. Vessey, M.P., et al.: Br Med J 2 (5599): 199–205, 1968. 30. Vessey, M.P., et al.: Br Med J 2 (5658): 651–657, 1969. 31. Porter, J.B., et al.: Obstet Gynecol 59 (3): 299–302, 1982. 32. Vessey, M.P., et al.: J Biosoc Sci 8: 373–427, 1976. 33. Mishell, D.R., et al.: Reproductive Endocrinology, Philadelphia, F.A. Davis Co., 1979. 34. Petitti, D.B., et al.: Lancet 2: 234–236, 1978. 35. Collaborative Group for the Study of Stroke in Young Women: JAMA 231 (7): 718–722, 1975. 36. Inman, W.H., et al.: Br Med J 2: 203–209, 1970. 37. Meade, T.W., et al.: Br Med J 280 (6224): 1157–1161, 1980. 38. Kay, C.R.: Am J Obstet Gynecol 142 (6): 762–765, 1982. 39. Gordon, T., et al.: Am J Med 62: 707–714, 1977. 40. Royal College of General Practitioners’ Oral Contraception Study: J Coll Gen Pract 33: 75–82, 1983. 41. Ory, H.W.: Fam Plann Perspect 15 (2): 57–63, 1983. 42. Paul, C., et al.: Br Med J 293: 723–725, 1986. 43. The Cancer and Steroid Hormone Study of the Centers for Disease Control: N Engl J Med 315 (7): 405–411, 1986. 44. Pike, M.C., et al.: Lancet 2: 926–929, 1983. 45. Miller, D.R., et al.: Obstet Gynecol 68: 863–868, 1986. 46. Olsson, H., et al.: Lancet 2: 748–749, 1985. 47. McPherson, K., et al.: Br J Cancer 56: 653–660, 1987. 48. Huggins, G.R., et al.: Fertil Steril 47 (5): 733–761, 1987. 49. McPherson, K., et al.: Br Med J 293: 709–710, 1986. 50. Ory, H., et al.: Am J Obstet Gynecol 124 (6): 573–577, 1976. 51. Vessey, M.P., et al.: Lancet 2: 930, 1983. 52. Brinton, L.A., et al.: Int J Cancer 38: 339–344, 1986. 53. WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Br Med J 290: 961–965, 1985. 54. Rooks, J.B., et al.: JAMA 242 (7): 644–648, 1979. 55. Bein, N.N., et al.: Br J Surg 64: 433–435, 1977. 56. Klatskin, G.:Gastroenterology 73: 386–394, 1977. 57. Henderson, B.E., et al.: Br J Cancer 48: 437–440, 1983. 58. Neuberger, J., et al.: Br Med J 292: 1355–1357, 1986. 59. Forman, D., et al.: Br Med J 292: 1357–1361, 1986. 60. Harlap, S., et al.: Obstet Gynecol 55 (4): 447–452, 1980. 61. Savolainen, E., et al.: Am J Obstet Gynecol 140 (5): 521–524, 1981. 62. Janerich, D.T., et al.: Am J Epidemiol 112 (1): 73–79, 1980. 63. Ferencz, C., et al.: Teratology 21: 225–239, 1980. 64. Rothman, K.J., et al.: Am J Epidemiol 109 (4): 433–439, 1979. 65. Boston Collaborative Drug Surveillance Program: Lancet 1: 1399–1404, 1973. 66. Royal College of General Practitioners: Oral contraceptives and health. NewYork, Pittman, 1974. 67. Rome Group for the Epidemiology and Prevention of Cholelithiasis: Am J Epidemiol 119 (5): 796–805, 1984. 68. Strom, B.L., et al.: Clin Pharmacol Ther 39 (3): 335–341, 1986. 69. Perlman, J.A., et al.: J Chronic Dis 38 (10): 857–864, 1985. 70. Wynn, V., et al.: Lancet 1: 1045–1049, 1979. 71. Wynn, V.: Progesterone and Progestin, New York, Raven Press, 1983. 72. Wynn, V., et al.: Lancet 2: 720–723, 1966. 73. Fisch, I.R., et al.: JAMA 237 (23): 2499–2503, 1977. 74. Laragh, J.H.: Am J Obstet Gynecol 126 (1): 141–147, 1976. 75. Ramcharan, S., et al.: Pharmacology of Steroid Contraceptive Drugs, New York, Raven Press, 1977. 76. Stockley, I.: Pharm J 216: 140–143, 1976. 77. Dickey, R.P.: Managing Contraceptive Pill Patients, Oklahoma, Creative Informatics Inc., 1984. 78. Porter, J.B., Hunter, J., Jick, H., et al.: Obstet Gynecol 1985; 66: 1–4. 79. Porter, J.B., Hershel, J., Walker, A.M.: Obstet Gynecol 1987; 70: 29–32. 80. Fertility and Maternal Health Drugs Advisory Committee, F.D.A., October, 1989. 81. Schlesselman, J., Stadel, B.V., Murray, P., Lai, S.: Breast cancer in relation to early use of oral contraceptives. JAMA 1988; 259: 1828–1833. 82. Hennekens, C.H., Speizer, F.E., Lipnick, R.J., Rosner, B., Bain, C., Belanger, C., Stampfer, M.J., Willett, W., Peto, R.: A case-control study of oral contraceptive use and breast cancer. JNCI 1984; 72: 39–42. 83. Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J Coll Gen Pract 28: 393–399, 1978. 84. Royal College of General Practitioners’ Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1: 624, 1977.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2023. All Rights Reserved.